Konstantinos Efthymiopoulos
Konstantinos has more than 20 years of international experience in the pharmaceutical, biotechnology and drug delivery industry, covering all aspects of drug discovery, development, registration and launch. He worked in a wide range of therapeutic areas, including dermatology, rheumatology, gastroenterology, anti-infectives, CNS, cardiovascular and oncology. Prior to joining FXT, Konstantinos worked for Eurand, based in Milan, Italy, as the Chief Scientific Officer of the company, responsible for R&D worldwide. Previous appointments include Corporate VP, Head of the Dermatology Therapeutic Area and Corporate VP, Head of the New Therapies Area within Marketing and Sales with Serono, based in Geneva, Switzerland, and various management roles within Clinical Pharmacology with Glaxo/Glaxo Wellcome, based in London, UK and within Drug Metabolism and Pharmacokinetics with Farmitalia Carlo Erba, based in Milan, Italy.
Konstantinos has a Pharmacy degree from the University of Athens, an M.Sc. in Industrial Pharmacy and an M.Sc. in Molecular and Cellular Pharmacology and Medicinal Chemistry as well as a Ph.D. in Pharmacology (Pharmacokinetics) from the University of Strasbourg. He also holds an M.B.A. from the London Business School. He is author/co-author of more than 60 scientific publications and of two patents, is regularly invited to speak in international scientific and business conferences and has held visiting Professor appointments at the Universities of Strasbourg and Padua. Konstantinos is currently also President of Eporgen Venture SpA and an Advisor to Index Ventures